直近一年間の累計
アクセス数 : ?
ダウンロード数 : ?
ID 117032
著者
板東, 浩 Tokushima University|Japan Low Carbohydrate Diet Promotion Association KAKEN研究者をさがす
キーワード
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs)
Oral semaglutide (Rybelsus)
Sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC)
Peptide Innovation for early diabetes treatment (PIONEER)
Adverse effects (AEs)
資料タイプ
学術雑誌論文
抄録
As one of the Glucagon-like peptide 1 receptor agonists (GLP-1 RAs), oral semaglutide (Rybelsus) become first ingestible agent by absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). It was clinically investigated by Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) trials. Pharmacologically, blood concentration of semaglutide is kept higher when fasting time period after intake becomes longer. It is provided for increasing doses of 3 mg, 7 mg, 14 mg in every month. Rybelsus showed higher ratio of adverse effects (AEs), which include gastrointestinal dysfunction and headache. This agent is a novel delivery of therapeutic peptide and become life-changing beneficial agents for diabetic patients.
掲載誌名
Journal of Diabetes, Obesity & Metabolism
出版者
Yumed Text
5
1
開始ページ
e108
発行日
2022-04-24
権利情報
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/).
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
医学系